Elevated interleukin-1β induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice

Brain Research

Volumn 1302, Issue , 2009, Pages 256-264

  Bian, Min juan ^a   Li, Li mei ^b   Yu, Mei ^a   Fei, Jian ^b,c   Huang, Fang ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Research Center for Model Organisms   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

Interleukin 1 ; Luciferase; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; LUCIFERASE; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; DOPAMINE; MESSENGER RNA; NEUROTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; IN VIVO STUDY; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SUBSTANTIA NIGRA; AGE; AGING; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; GLIOSIS; IMMUNOLOGY; METABOLISM; NERVE CELL; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PROMOTER REGION; SEXUAL DEVELOPMENT; TRANSGENIC MOUSE; UPREGULATION;

MUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AGE FACTORS; AGING; ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; GENE EXPRESSION REGULATION; GENETIC MARKERS; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LUCIFERASES; MALE; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NEURONS; NEUROTOXINS; PARKINSONIAN DISORDERS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SEX CHARACTERISTICS; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 72149100983     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.07.030     Document Type: Article

References (39)

1. Arai H., Furuya T., Yasuda T., Miura M., Mizuno Y., and Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J. Biol. Chem. 279 (2004) 51647-51653
2. Batchelor P.E., Liberatore G.T., Wong J.Y., Porritt M.J., Frerichs F., Donnan G.A., and Howells D.W. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19 (1999) 1708-1716
3. Bian M., Yu M., Yang S., Gao H., Huang Y., Deng C., Gao Y., Sun F., and Huang F. Expression of Cbl-interacting protein of 85 kDa in MPTP mouse model of Parkinson's disease and 1-methyl-4-phenyl-pyridinium ion-treated dopaminergic SH-SY5Y cells. Acta Biochim. Biophys. Sin. (Shanghai) 40 (2008) 505-512
4. Cassarino D.S., Fall C.P., Swerdlow R.H., Smith T.S., Halvorsen E.M., Miller S.W., Parks J.P., Parker Jr. W.D., and Bennett Jr. J.P. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362 (1997) 77-86
5. Ciesielska A., Joniec I., Kurkowska-Jastrzebska I., Przybylkowski A., Gromadzka G., Czlonkowska A., and Czlonkowski A. Influence of age and gender on cytokine expression in a murine model of Parkinson's disease. Neuroimmunomodulation 14 (2007) 255-265
6. D'Astous M., Mendez P., Morissette M., Garcia-Segura L.M., and Di Paolo T. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol. Pharmacol. 69 (2006) 1492-1498
7. Diamond S.G., Markham C.H., Hoehn M.M., McDowell F.H., and Muenter M.D. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 40 (1990) 763-766
8. Dluzen D.E., McDermott J.L., and Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol. Teratol. 18 (1996) 603-606
9. Dluzen D.E., McDermott J.L., and Anderson L.I. Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotox. Res. 3 (2001) 291-300
10. Eddleston M., and Mucke L. Molecular profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience 54 (1993) 15-36
11. Garcia-Segura L.M., Naftolin F., Hutchison J.B., Azcoitia I., and Chowen J.A. Role of astroglia in estrogen regulation of synaptic plasticity and brain repair. J. Neurobiol. 40 (1999) 574-584
12. Hebert G., Arsaut J., Dantzer R., and Demotes-Mainard J. Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci. Lett. 349 (2003) 191-195
13. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., and Hirsch E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72 (1996) 355-363
14. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., and Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19 (1999) 3440-3447
15. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., and Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991) 230-232
16. Jones N.C., Prior M.J., Burden-Teh E., Marsden C.A., Morris P.G., and Murphy S. Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes. Eur. J. Neurosci. 22 (2005) 72-78
17. Joniec I., Ciesielska A., Kurkowska-Jastrzebska I., Przybylkowski A., Czlonkowska A., and Czlonkowski A. Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. (2009)
18. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., and Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39 (1998) 167-180
19. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46 (1999) 598-605
20. Lepagnol-Bestel A.M., Maussion G., Ramoz N., Moalic J.M., Gorwood P., and Simonneau M. Nrsf silencing induces molecular and subcellular changes linked to neuronal plasticity. NeuroReport 18 (2007) 441-446
21. Li L., Fei Z., Ren J., Sun R., Liu Z., Sheng Z., Wang L., Sun X., Yu J., Wang Z., and Fei J. Functional imaging of interleukin 1 beta expression in inflammatory process using bioluminescence imaging in transgenic mice. BMC Immunol. 9 (2008) 49
22. Mason J.L., Suzuki K., Chaplin D.D., and Matsushima G.K. Interleukin-1beta promotes repair of the CNS. J. Neurosci. 21 (2001) 7046-7052
23. McGeer P.L., Yasojima K., and McGeer E.G. Inflammation in Parkinson's disease. Adv. Neurol. 86 (2001) 83-89
24. McGuire S.O., Ling Z.D., Lipton J.W., Sortwell C.E., Collier T.J., and Carvey P.M. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp. Neurol. 169 (2001) 219-230
25. Miller D.B., Ali S.F., O'Callaghan J.P., and Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. N. Y. Acad. Sci. 844 (1998) 153-165
26. Mocchetti I., Bachis A., Nosheny R.L., and Tanda G. Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons. Neurotox. Res. 12 (2007) 135-143
27. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., and Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180 (1994) 147-150
28. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., and Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211 (1996) 13-16
29. Ramirez A.D., Liu X., and Menniti F.S. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 77 (2003) 223-231
30. Rozovsky I., Wei M., Stone D.J., Zanjani H., Anderson C.P., Morgan T.E., and Finch C.E. Estradiol (E2) enhances neurite outgrowth by repressing glial fibrillary acidic protein expression and reorganizing laminin. Endocrinology 143 (2002) 636-646
31. Sortino M.A., Chisari M., Merlo S., Vancheri C., Caruso M., Nicoletti F., Canonico P.L., and Copani A. Glia mediates the neuroprotective action of estradiol on beta-amyloid-induced neuronal death. Endocrinology 145 (2004) 5080-5086
32. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., and Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59 (1992) 99-106
33. Tripanichkul W., Sripanichkulchai K., and Finkelstein D.I. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. Brain Res. 1084 (2006) 28-37
34. Tsang K.L., Ho S.L., and Lo S.K. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 54 (2000) 2292-2298
35. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., and Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157 (2003) 1015-1022
36. Wahner A.D., Bronstein J.M., Bordelon Y.M., and Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69 (2007) 1836-1842
37. Wooten G.F., Currie L.J., Bovbjerg V.E., Lee J.K., and Patrie J. Are men at greater risk for Parkinson's disease than women?. J. Neurol. Neurosurg. Psychiatry 75 (2004) 637-639
38. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
39. Zhang R., Zhang Z., Wang L., Wang Y., Gousev A., Zhang L., Ho K.L., Morshead C., and Chopp M. Activated neural stem cells contribute to stroke-induced neurogenesis and neuroblast migration toward the infarct boundary in adult rats. J. Cereb. Blood Flow Metab. 24 (2004) 441-448